Amgen Inc. $AMGN Holdings Trimmed by CENTRAL TRUST Co

CENTRAL TRUST Co lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,440 shares of the medical research company’s stock after selling 3,011 shares during the period. CENTRAL TRUST Co’s holdings in Amgen were worth $10,945,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Hoya Capital Real Estate LLC bought a new position in Amgen during the fourth quarter valued at about $218,000. Core Alternative Capital boosted its stake in Amgen by 9.2% during the fourth quarter. Core Alternative Capital now owns 3,653 shares of the medical research company’s stock valued at $1,196,000 after buying an additional 308 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV boosted its stake in Amgen by 10.9% during the fourth quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 11,697 shares of the medical research company’s stock valued at $3,828,000 after buying an additional 1,154 shares in the last quarter. Oak Harbor Wealth Partners LLC boosted its stake in Amgen by 3.7% during the fourth quarter. Oak Harbor Wealth Partners LLC now owns 4,398 shares of the medical research company’s stock valued at $1,440,000 after buying an additional 156 shares in the last quarter. Finally, Souders Financial Advisors boosted its stake in Amgen by 1.7% during the fourth quarter. Souders Financial Advisors now owns 5,328 shares of the medical research company’s stock valued at $1,744,000 after buying an additional 88 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Citigroup increased their price target on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Argus increased their price target on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Guggenheim increased their price target on Amgen from $347.00 to $351.00 and gave the company a “neutral” rating in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $357.54.

Amgen Trading Down 4.7%

Shares of NASDAQ AMGN opened at $329.82 on Friday. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The firm has a market capitalization of $178.00 billion, a PE ratio of 22.95, a PEG ratio of 3.26 and a beta of 0.44. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The business has a 50-day moving average price of $358.07 and a two-hundred day moving average price of $340.79.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 139.90% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the company posted $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts predict that Amgen Inc. will post 22.28 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double?digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long?term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight?loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY?2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in?line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical?trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in?line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near?term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.